Q4 EPS Estimates for Alpha Cognition Lifted by HC Wainwright

Alpha Cognition Inc. (NASDAQ:ACOG) – HC Wainwright boosted their Q4 2027 earnings per share estimates for Alpha Cognition in a report issued on Monday, August 17th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.01 per share for the quarter, up from their prior forecast of ($0.01). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Alpha Cognition’s current full-year earnings is ($1.37) per share.

A number of other equities analysts have also recently issued reports on ACOG. Craig Hallum restated a “buy” rating and set a $17.00 target price on shares of Alpha Cognition in a research report on Friday. Wall Street Zen upgraded Alpha Cognition from a “sell” rating to a “hold” rating in a research report on Saturday. Maxim Group began coverage on Alpha Cognition in a research note on Friday, May 29th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, Raymond James Financial started coverage on Alpha Cognition in a report on Friday, July 10th. They set an “outperform” rating and a $20.00 target price on the stock. Four research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $17.25.

Alpha Cognition Price Performance

NASDAQ:ACOG opened at $8.84 on Tuesday. The company has a market capitalization of $192.45 million, a PE ratio of -8.04 and a beta of 2.30. Alpha Cognition has a 52-week low of $4.50 and a 52-week high of $10.00. The stock has a fifty day simple moving average of $7.80 and a 200-day simple moving average of $6.55.

Alpha Cognition (NASDAQ:ACOG) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.01). Alpha Cognition had a negative return on equity of 54.60% and a negative net margin of 153.61%.The business had revenue of $6.00 million during the quarter, compared to analysts’ expectations of $4.38 million.

Hedge Funds Weigh In On Alpha Cognition

Several institutional investors and hedge funds have recently modified their holdings of the company. Opaleye Management Inc. boosted its position in Alpha Cognition by 1,698.5% during the fourth quarter. Opaleye Management Inc. now owns 2,070,784 shares of the company’s stock worth $13,460,000 after acquiring an additional 1,955,642 shares during the last quarter. AWM Investment Company Inc. acquired a new position in Alpha Cognition in the 2nd quarter valued at $12,073,000. Ikarian Capital LLC raised its holdings in Alpha Cognition by 11.6% in the 4th quarter. Ikarian Capital LLC now owns 1,056,259 shares of the company’s stock valued at $6,866,000 after acquiring an additional 110,000 shares during the last quarter. Cable Car Capital LP lifted its stake in shares of Alpha Cognition by 68.8% during the 2nd quarter. Cable Car Capital LP now owns 869,002 shares of the company’s stock worth $8,108,000 after purchasing an additional 354,278 shares during the period. Finally, Sphera Funds Management LTD. boosted its holdings in shares of Alpha Cognition by 67.6% during the fourth quarter. Sphera Funds Management LTD. now owns 567,616 shares of the company’s stock worth $3,690,000 after purchasing an additional 228,864 shares during the last quarter.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.